



ABIVAX publishes 2016 shareholder newsletter *HIV drug candidate ABX464 and the history of HIV/AIDS*

Paris, May 9th, 2016 - ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that it has published its first shareholder newsletter, highlighting the history of HIV/AIDS and ABIVAX's HIV drug candidate, ABX464, which is in mid-stage clinical testing.

Currently available therapies are able to control the disease in most patients with HIV/AIDS, but there is still a large medical need for treatments that offer a functional cure or real cure. ABX464 may have the potential to provide a functional cure for HIV/AIDS because it does not appear to induce resistance and has a long-lasting effect. Formulated as a once-daily oral pill, ABX464 is easy to use. In testing to-date, its tolerability profile has been consistent with that of marketed HIV drugs.

Further information on ABIVAX, the history and current state of HIV/AIDS, and the innovative drug candidate ABX464 is available in the ABIVAX April 2016 newsletter, available by clicking [here](#).

ABIVAX is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and therapeutic vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. A recently updated corporate presentation, which includes a timeline for the company's anticipated news flow, is available at www.abivax.com.

Follow us on Twitter [@ABIVAX](#)

Contacts

Investor Relations

Raquel Lizarraga
raquel.lizarraga@abivax.com
+33 1 53 83 09 63

Citigate Dewe Rogerson

Antoine Denry/Alexandre Dechaux
abivax@citigate.fr
+33 1 53 32 84 75

LifeSci Advisors

Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254

Press Relations

ALIZE RP
Caroline Carmagnol/Margaux Pronost
abivax@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 65